Combined Abrocitinib and Acitretin Therapy for Darier’s Disease: A Case Report

Darier's disease (DD) is a rare chronic keratinizing skin disease characterized by dyskeratosis of epidermal cells. We report a case of DD with a medical history spanning over 20 years and recurring symptoms. Pathologically confirmed DD was treated with a combination of abrocitinib and acitretin, resulting in rapid symptom resolution within 2 weeks. No recurrence was noted in an 11-week follow-up. The mechanism may involve acitretin's inhibition of proliferation and anti-inflammation, while abrocitinib acts on IL-6 implicated in DD pathogenesis, exerting an immunomodulatory and anti-inflammatory effect, leading to rapid symptom relief. The combination of abrocitinib and acitretin is an effective therapy for DD, offering a promising new option for refractory patients.

Authors

Institutions

Publication Details

Journal
Clinical Cosmetic and Investigational Dermatology
Published
2024-12-01
DOI
https://doi.org/10.2147/ccid.s485694
Citations
2
Primary Topic
Genetic and rare skin diseases.
Type
article
Field-Weighted Citation Impact
1.10
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Combined Abrocitinib and Acitretin Therapy for Darier’s Disease: A Case Report

Xibao Zhang, Wenyan Liu, Jingyao Liang, Hui Ye et al.
2 citations
Clinical Cosmetic and Investigational Dermatology
Genetic and rare skin diseases.
1.10
article

Combined Abrocitinib and Acitretin Therapy for Darier’s Disease: A Case Report

Xibao Zhang, Wenyan Liu, Jingyao Liang, Hui Ye, Weifeng Chen, Junhui Zhu
article en
2 citations

Abstract

Darier's disease (DD) is a rare chronic keratinizing skin disease characterized by dyskeratosis of epidermal cells. We report a case of DD with a medical history spanning over 20 years and recurring symptoms. Pathologically confirmed DD was treated with a combination of abrocitinib and acitretin, resulting in rapid symptom resolution within 2 weeks. No recurrence was noted in an 11-week follow-up. The mechanism may involve acitretin's inhibition of proliferation and anti-inflammation, while abrocitinib acts on IL-6 implicated in DD pathogenesis, exerting an immunomodulatory and anti-inflammatory effect, leading to rapid symptom relief. The combination of abrocitinib and acitretin is an effective therapy for DD, offering a promising new option for refractory patients.

Clinical Cosmetic and Investigational DermatologyVol. Volume 17
Guangzhou Institute of Dermatology (CN), Guangzhou Medical University (CN)
Openalex Percentile: Top 18%
Genetic and rare skin diseases.
1.10
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.